Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Nevirapine products are in shortage in Canada (1 of 6 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
An antiretroviral medicine used as part of HIV treatment.
Products affected
1 / 6
In shortage since
Feb 2, 2026
Reports on file
12
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · since Feb 2, 2026, no end estimate · Shortage of an active ingredient.
Resolved
MYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · ended Mar 18, 2025 · Shortage of an active ingredient.
Resolved
MYLAN-NEVIRAPINE
200MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02387727 · ended Mar 3, 2025 · Delay in shipping of the drug.
Resolved
AURO-NEVIRAPINE
200MG · TABLET · AURO PHARMA INC
DIN 02318601 · ended Oct 28, 2024 · Demand increase for the drug.
Resolved
AURO-NEVIRAPINE
200MG · TABLET · AURO PHARMA INC
DIN 02318601 · ended Feb 26, 2024 · Demand increase for the drug.
Resolved
JAMP NEVIRAPINE
200MG · TABLET
TABLET · JAMP PHARMA CORPORATION
DIN 02405776 · ended Sep 2, 2022 · Disruption of the manufacture of the drug.
DIN 02387727 · ended Aug 27, 2018 · Delay in shipping of the drug.
Resolved
APO-NEVIRAPINE XR
400MG · TABLET (EXTENDED-RELEASE) · APOTEX INC
DIN 02427931 · ended Aug 29, 2017 · Disruption of the manufacture of the drug.
What's happening
Nevirapine is currently affected by an active shortage report filed with Health Canada by MYLAN PHARMACEUTICALS ULC.
The reported cause is: shortage of an active ingredient. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Nevirapine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AG).
Recent changes
No changes recorded yet.
Common questions
What is Nevirapine used for?
An antiretroviral medicine used as part of HIV treatment.
When will Nevirapine be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Nevirapine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.